Go Pro
NASDAQ:COCH

Envoy Medical Q1 2026 Earnings Report

Envoy Medical logo
$0.75 0.00 (-0.05%)
As of 08/21/2026 04:00 PM Eastern

Envoy Medical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.10 million
Beat/Miss
Missed by -$61.00 thousand
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Envoy Medical's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Envoy Medical Earnings Headlines

HC Wainwright Lowers Envoy Medical (NASDAQ:COCH) Price Target to $2.00
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
ENVOY MEDICAL INC 0,691 +2,92 %
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile